Core Viewpoint - The article addresses common questions regarding the oral formulation of Semaglutide for weight loss, emphasizing its effectiveness, usage guidelines, and safety profile while highlighting ongoing clinical trials and research findings [4]. Group 1: Weight Loss Efficacy - In the OASIS 1 study, participants using 50mg oral Semaglutide lost an average of 17.4% (18.34 kg) over 68 weeks [5][6]. - The OASIS 4 study showed that participants using 25mg oral Semaglutide lost an average of 13.6% (14.4 kg) over 64 weeks, with potential weight loss reaching 16.6% (17.6 kg) if all subjects completed the treatment [7][8]. Group 2: Side Effects and Safety - Approximately 30% of participants reported gastrointestinal side effects, which were mostly mild to moderate and tended to resolve over time [9]. - Semaglutide has shown good safety in elderly patients and those with renal impairment, although caution is advised for patients with severe renal dysfunction [11]. Group 3: Usage Guidelines - Semaglutide should be taken at least 30 minutes before the first meal of the day, using no more than 118ml of water, and should not be crushed or chewed [12]. - The recommended starting dose is 3mg once daily, increasing to 7mg after 30 days, with a maximum dose of 14mg if necessary [12]. Group 4: Lifestyle Changes - Weight loss should not solely rely on dieting; a balanced intake of at least 1200 calories per day is recommended, with a focus on healthy snacks [13]. - Adequate protein intake of at least 1g per kg of body weight is essential, and physical activity of 150-300 minutes per week is advised [15]. Group 5: Mechanism of Action - Semaglutide mimics GLP-1 hormone, improving insulin secretion and reducing appetite, while also slowing gastric emptying to prolong satiety [16]. - The SNAC technology enhances the absorption of Semaglutide, increasing its bioavailability by approximately 100 times [16]. Group 6: Contraindications - Semaglutide is not suitable for type 1 diabetes patients, those with severe gastrointestinal diseases, or individuals with a history of medullary thyroid carcinoma [18]. Group 7: Additional Benefits - Clinical trials have shown that Semaglutide effectively manages type 2 diabetes, with a 92.3% HbA1c target achievement rate among newly diagnosed patients in China [19]. - The PIONEER 6 study indicated a 51% reduction in cardiovascular death risk for patients using Semaglutide compared to placebo [21]. Group 8: Oral vs. Injectable Formulation - Oral Semaglutide is easier to store and transport compared to injectable forms, which require strict cold chain logistics [23]. - The oral formulation is more convenient for patients who may have a fear of injections [23]. Group 9: Risk of Hypoglycemia - Semaglutide's glucose-dependent mechanism means it does not cause hypoglycemia in individuals with normal blood sugar levels, making it safer for weight loss treatments [24]. Group 10: Weight Regain After Discontinuation - In studies, 18% of patients regained weight after stopping Semaglutide, while 56% maintained or continued to lose weight [25].

Core Viewpoint - The company reported significant growth in its financial performance for the year 2025, driven by increased demand in the peptide drug market, particularly in the areas of glucose-lowering and weight-loss medications [2][4]. Financial Data and Indicators - The company achieved an operating income of 741.34 million yuan, representing a year-on-year increase of 62.55% [2]. - The net profit attributable to the parent company was 165.82 million yuan, up 231.49% from the previous year [2]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 172.65 million yuan, reflecting a growth of 278.52% [2]. Financial Condition - As of the end of 2025, the total assets of the company amounted to 1.937 billion yuan, an increase of 17.55% compared to the beginning of the reporting period [3]. - The equity attributable to the parent company was 1.065 billion yuan, which is a growth of 16.02% from the start of the period [3]. Factors Influencing Operating Performance - The company's focus on the synergistic development of its core business in peptide drug CDMO, raw materials, and formulations has led to a significant increase in sales of GLP-1 raw materials, contributing to the substantial improvement in operating performance [4]. - The increase in total operating income, operating profit, total profit, and net profit attributable to the parent company, as well as the basic earnings per share, was primarily due to the company's proactive expansion of its raw material market both domestically and internationally [5]. Changes Exceeding 30% - The company experienced significant changes exceeding 30% in various financial metrics, attributed to the successful implementation of new production capacity and increased sales of semaglutide and teriparatide raw materials [5]. - The company's share capital increased by more than 30% due to a capital reserve conversion, resulting in an increase in the number of shares from 112,418,556 to 157,385,978 [5].

Core Viewpoint - The article highlights the journey of actor Liu Jingshan and the success story of a patient known as "the first fat man in China," who lost over 400 pounds with the help of the Metabolic Weight Loss Center at the China-Japan Friendship Hospital, emphasizing the importance of healthy eating and weight management during the festive season [1][6]. Group 1: Liu Jingshan's Experience - Liu Jingshan, a well-known actor, has a personal connection to food, often reflecting on his family's culinary traditions and his own struggles with weight due to his acting roles [3][4]. - He has experienced health issues related to being overweight, including high blood pressure and injuries from filming, which limit his ability to exercise [4]. Group 2: Weight Loss Success Story - The article features a patient who previously weighed over 700 pounds and successfully lost more than 400 pounds, improving his health metrics significantly, including the resolution of fatty liver disease [6]. - The medical team from the China-Japan Friendship Hospital shared insights on effective weight loss strategies and tips for maintaining stable blood sugar levels during festive meals [6].

Core Viewpoint - The article emphasizes the importance of a comprehensive approach to weight loss, highlighting that medication alone, such as semaglutide, is insufficient without lifestyle changes and professional guidance [4]. Group 1: Medication and Professional Guidance - The introduction of semaglutide in medical institutions has led to an increase in consultations at weight loss and endocrinology clinics [4] - It is recommended that patients seeking weight loss consult qualified medical professionals for proper assessment and diagnosis to create a scientific weight loss plan [4] - The use of weight loss medications requires standardized management, and reliance solely on medication is unlikely to yield effective results [4] Group 2: Dietary Recommendations During Medication - Maintaining a balanced diet is crucial while taking semaglutide, with recommendations to reduce refined carbohydrates and sugary drinks, and to limit salt intake to 5 grams per day [6] - During dinner, it is advised to avoid greasy and sweet foods, opting for light and easily digestible options to prevent gastrointestinal discomfort [6] Group 3: Foods to Avoid - High-fat foods, such as fried items and heavily cooked dishes, should be avoided as they can cause gastrointestinal discomfort, especially when taking semaglutide [7] - Foods high in trans fats and saturated fats, including full-fat dairy products and red meats, can exacerbate gastrointestinal issues and affect medication efficacy [7] - High-sugar foods, including sauces, baked goods, and sugary drinks, should be strictly controlled to prevent blood sugar fluctuations, particularly for diabetic patients [7] - High-sodium foods, such as chips and pickled products, can increase blood pressure and pose risks for heart disease, especially in type 2 diabetes patients [9] - Refined carbohydrates and high-sugar starchy vegetables should be minimized, with a preference for whole grains and low-sugar vegetables to better align with semaglutide's effects [9] - Alcohol should be reduced or avoided as it can aggravate digestive issues and increase the risk of hypoglycemia while on semaglutide [10]

Core Viewpoint - The key to weight loss is controlling the balance of energy intake and expenditure, where energy intake must be less than energy expenditure to achieve weight loss [1] Group 1 - Consuming only boiled vegetables in large quantities, along with high-energy foods like potato chips and starchy vegetables, can lead to weight gain [1] - A diet consisting solely of boiled vegetables without meat, eggs, dairy, or fruits may not provide all necessary nutrients, such as high-quality proteins and fats, potentially leading to malnutrition and health issues [1]

Core Viewpoint - The Chengdu Third People's Hospital's obesity and metabolic disease center has seen a significant increase in patients seeking weight loss solutions, indicating a shift towards proactive health management rather than reactive treatment after health issues arise [8][11]. Group 1: Patient Demographics and Trends - The obesity and metabolic disease center has completed a total of 6,835 weight loss surgeries, with a notable increase in patients who are overweight but not yet experiencing health complications [6][8]. - Approximately 40% of the new outpatient visits are from overweight patients who are taking the initiative to manage their weight before developing related health issues [8]. - The center emphasizes that obesity is not solely determined by appearance, as many patients with normal weight may still suffer from metabolic disorders [11]. Group 2: Health Implications and Treatment - The center's approach includes a comprehensive analysis of body composition and metabolic rates, with over 50 data points used to assess obesity scientifically [10]. - Current statistics indicate that 34.3% of the population is overweight and 16.4% is obese, meaning over 700 million people in China are affected by weight issues [11]. - The center reports that 80% to 90% of obesity-related complications can be alleviated through weight loss, with significant improvements in conditions like type 2 diabetes and hypertension [12][15]. Group 3: Psychological and Lifestyle Changes - The treatment process at the center not only focuses on physical health but also addresses the psychological aspects of obesity, with many patients experiencing emotional relief post-surgery [13][15]. - Patients are encouraged to adopt sustainable lifestyle changes, as relying solely on medication for weight maintenance is often ineffective [14]. - The concept of "rebirth" is prevalent among patients, who express a desire to regain control over their lives and health through weight loss [15].

Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HRS-7535, a novel oral small molecule GLP-1 receptor agonist aimed at treating type 2 diabetes and weight loss [1] Group 1: Product Development - HRS-7535 is designed to activate GLP-1 receptors, promoting insulin secretion from the pancreas, reducing glucagon secretion, and suppressing gastric emptying [1] - The drug also enhances satiety and suppresses appetite through central mechanisms, leading to reduced energy intake [1] - There are currently no oral small molecule GLP-1 receptor agonists available in the global market [1] Group 2: Financial Investment - The cumulative research and development investment for HRS-7535 has reached approximately 369.4 million yuan [1]

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HRS-7535 tablets, which will commence shortly [1] Group 1: Product Information - HRS-7535 tablets are a novel oral small molecule GLP-1 receptor agonist designed to treat type 2 diabetes (T2DM) and aid in weight loss [1] - The mechanism of HRS-7535 includes activating GLP-1 receptors to promote insulin secretion from the pancreas, reduce glucagon secretion, and inhibit gastric emptying [1] - Additionally, HRS-7535 influences the central nervous system to enhance satiety and suppress appetite, leading to a direct reduction in energy intake [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-7535 tablets, a new oral small molecule GLP-1 receptor agonist aimed at treating type 2 diabetes and weight loss [1]. Group 1: Product Development - The clinical trial approval for HRS-7535 tablets will allow the company to initiate trials in the near future [1]. - HRS-7535 functions by activating GLP-1 receptors, which promotes insulin secretion from the pancreas, reduces glucagon secretion, and inhibits gastric emptying [1]. - The drug also enhances satiety and suppresses appetite through central mechanisms, leading to reduced energy intake [1]. Group 2: Market Implications - The introduction of HRS-7535 could provide a new treatment option for type 2 diabetes (T2DM) patients, addressing both glycemic control and weight management [1].

Core Viewpoint - The article emphasizes the importance of sustainable weight management and highlights the challenges faced by individuals in maintaining weight loss, particularly for those with moderate to severe obesity. It discusses the shift towards surgical interventions as a preferred treatment option for obesity, as traditional methods like diet and exercise often prove ineffective for this demographic [3][5]. Group 1: Weight Management Trends - The Chinese government is promoting a "Weight Management Year" initiative to encourage healthy lifestyles, making weight loss a frequent topic of discussion [1]. - The article features a case study of Mr. Ge, who successfully reduced his weight from 297 pounds to 128 pounds through surgical intervention and lifestyle changes [3]. Group 2: Medical Insights on Obesity - Medical professionals indicate that for individuals with moderate to severe obesity, relying solely on diet and exercise for weight loss is often unsuccessful. The 2024 obesity treatment guidelines recommend prioritizing surgical options [5]. - Obesity is described as a medical condition rather than a matter of willpower, with many patients experiencing insulin resistance and related health issues that complicate weight loss efforts [5]. Group 3: Practical Weight Loss Tips - It is advised to maintain three meals a day to prevent metabolic slowdown, which can hinder weight loss efforts [6]. - Adjusting the order of food consumption—starting with soup, then vegetables and protein, followed by carbohydrates—can aid in weight management [7]. - Going to bed with a slight feeling of hunger is beneficial, as long as it is within a tolerable range, to avoid high insulin levels that can sabotage weight loss [8]. - Incorporating exercise into daily routines rather than using it as a compensatory measure for overeating is recommended, as the caloric burn from exercise is often insufficient to offset excessive food intake [8]. - Seeking professional guidance for personalized weight loss plans is encouraged, rather than attempting to lose weight independently [9].